WebBackground: Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). However, there is no established strategy for treatment following acquired resistance to this agent. One potential strategy for treating acquired resistance to EGFR … WebJul 2, 2024 · Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors Authors (first, second and last of 13) Eiki Ichihara
Treating Cancer with Immunotherapy Types of Immunotherapy
WebJul 28, 2024 · Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration ... Yukiko Kiniwa 12 , Ayako … WebJan 24, 2024 · Cancer Immunology, Immunotherapy - Pembrolizumab alone (IO-mono) ... Shinobu Hosokawa, Eiki Ichihara, … Katsuyuki Kiura. First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers. do chickens poop where they lay eggs
Real-world multicentre cohort of first-line pembrolizumab
WebJan 24, 2024 · Immunotherapy has been very successful for certain types of advanced cancers, such as lung, bladder, and skin cancers. One form of immunotherapy is called an immune checkpoint inhibitor. It takes the brakes off immune cells, unlocking their ability to detect altered proteins on cancer cells in order to attack and kill these cells. WebThe Cancer Immunology Program also pioneered immunotherapy with anti-PD1 checkpoint blockade drugs before surgery, which is expected to potentially become standard of care in a number of cancers, including … WebNov 28, 2024 · Cancer Immunology, Immunotherapy. Article. Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab ... Shinobu Hosokawa, Eiki Ichihara, … Katsuyuki Kiura. creative care factory